Myriad Genetics Conference Call Summary Company Overview - **Company**: Myriad Genetics (NasdaqGS:MYGN) - **Date**: March 10, 2026 - **Speakers**: CEO Sam Raha, CFO Ben Wheeler Key Points Management Insights - CEO Sam Raha purchased 40,000 shares, indicating personal conviction in the company's future [5][6] - The company is at a pivotal moment, focusing on a new strategy to serve the broader cancer care continuum, building on strengths in hereditary cancer [11][16] - There is a strong level of trust from customers based on product quality and scientific backing [14] Financial Guidance - The company projects a revenue midpoint of $870 million for 2026, expecting mid-single-digit sequential growth each quarter [23][25] - Historical trends show that the second half of the year typically contributes a higher proportion of annual revenue [27] - Key growth drivers include the launch of updated hereditary cancer panels and a dedicated sales channel for unaffected individuals [28][29] Product Performance - GeneSight is expected to grow mid-single-digit percentages, recovering from previous challenges [30] - The company added 12 payers for GeneSight last year, contributing to stability and growth potential [36] - The hereditary cancer segment saw a 6% annual growth, with a 9% growth in Q4, indicating positive momentum [33] Challenges and Solutions - The company faced challenges with UnitedHealthcare's non-coverage impacting GeneSight, but has focused on other growth opportunities [50] - Myriad has implemented new processes to enhance execution excellence, addressing past operational issues [84][86] - The order management system issues from the previous year have been resolved, and the company is optimistic about returning to growth in the prenatal segment [75][78] Upcoming Initiatives - The FirstGene mother-only assay is set to launch in Q3 2026, offering unique advantages such as earlier testing at eight weeks gestational age [101][104] - The company is focusing on expanding its market share in prenatal testing while minimizing cannibalization of existing products [106] Market Dynamics - The hereditary cancer market is expected to grow due to increasing cancer diagnoses, presenting opportunities for Myriad [74] - The company is actively working on enhancing its sales force and marketing strategies to drive growth in both hereditary and prenatal segments [58][59] ASP Considerations - Average Selling Prices (ASP) are expected to remain stable in 2026, with a slight decline anticipated due to product mix shifts [60][65] - The company experienced a 3% decline in ASP in 2025, primarily due to changes in UnitedHealthcare's policies [62] Conclusion - Myriad Genetics is positioning itself for growth through strategic product launches, improved operational execution, and a focus on customer trust and satisfaction. The company is optimistic about achieving its financial guidance and expanding its market presence in the coming years.

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $210 million, exceeding the high end of the pre-announced range, with a year-over-year growth of approximately 4% when excluding the impact from UnitedHealthcare's decision on GeneSight [6][25] - For the full year 2025, revenue was $824.5 million, with adjusted EBITDA of $14.3 million and adjusted EPS of $0.04, reflecting strong operational performance [8][28] - Adjusted gross margin for the fourth quarter was 70%, with adjusted operating expenses decreasing by $7 million year-over-year due to disciplined cost management [8][27] Business Line Data and Key Metrics Changes - Oncology revenue for the fourth quarter was $84.7 million, growing 2% year-over-year, with MyRisk test volume growth of 14% in the affected market and 11% in the unaffected market [16][18] - Prolaris revenue growth accelerated to 16% year-over-year in the fourth quarter, driven by 12% volume growth [16][17] - Women's health revenue was $88.5 million, an increase of 2% year-over-year, with hereditary cancer testing in the unaffected market growing by 3% and volume growth of 11% [18][19] - GeneSight revenue was $36.6 million, with volume growth of 9% year-over-year, despite challenges from UnitedHealthcare's coverage policy change [22][24] Market Data and Key Metrics Changes - The company served over 55,000 healthcare providers and delivered over 1.5 million test reports in 2025, indicating strong market penetration [8] - The mental health business saw a record number of ordering clinicians, exceeding 38,000 in the fourth quarter [22] Company Strategy and Development Direction - The company is focusing on high-growth market segments and plans multiple product launches, including the expanded MyRisk panel and the AI-enhanced Prolaris test [5][10] - The strategy includes strengthening commercial capabilities and expanding the sales team, with an investment of over $35 million to enhance organizational efficiency and growth [15][61] - The company aims to maintain leadership in urinary cancer testing while expanding into other cancer testing applications [9][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving high single-digit to low double-digit growth rates in 2027 and beyond, supported by new product launches and recovery in the prenatal business [39][40] - The company is optimistic about the potential for continued momentum in hereditary cancer testing and prenatal testing, with expectations for recovery in 2026 [20][21] Other Important Information - The company plans to simplify its reporting structure to align with its strategic focus areas, including cancer care continuum, prenatal health, and mental health [31][32] - The company is preparing for the commercial launch of Precise MRD for breast cancer, with an alpha launch starting next week [11][14] Q&A Session Summary Question: Confidence in long-term growth rate - Management highlighted the drivers of growth for 2026, including product launches and improvements in commercial execution, expressing confidence in returning to high single-digit growth rates [37][39] Question: MRD launch strategy - Management indicated a selective approach for the MRD launch, focusing on user experience and operational efficiency before expanding volume [40][42] Question: Prenatal growth expectations - Management acknowledged a decline in prenatal volume in Q1 but anticipated recovery in Q2 and beyond, supported by a focused sales team and new product launches [45][81] Question: Prolaris momentum and dynamics - Management noted that improved engagement with KOLs and expansion of the sales team contributed to Prolaris growth, while also acknowledging potential favorable comparisons in Q4 [74][76] Question: Customer impact from order management issues - Management emphasized the importance of addressing order management issues and expressed confidence in restoring customer relationships and achieving growth moving forward [86][88]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $210 million, exceeding the high end of the pre-announced range, with a year-over-year growth of approximately 4% when excluding the impact from UnitedHealthcare's decision on GeneSight [6][25] - For the full year 2025, revenue was $824.5 million, with adjusted EBITDA of $14.3 million and adjusted EPS of $0.04, reflecting disciplined cost management and strategic investments [8][28] - The adjusted gross margin for the fourth quarter was 70%, down approximately 190 basis points year-over-year due to the revenue headwind from GeneSight [9][26] Business Line Data and Key Metrics Changes - Oncology revenue for the fourth quarter was $84.7 million, with MyRisk test volume growth of 14% in the affected market and 11% in the unaffected market [16][18] - Prolaris revenue growth accelerated to 16% year-over-year in the fourth quarter, driven by a 12% increase in test volume [16][17] - Women's health revenue was $88.5 million, reflecting a 2% increase year-over-year, with hereditary cancer testing in the unaffected market growing by 3% and volume growth of 11% [18][19] Market Data and Key Metrics Changes - GeneSight volume grew 9% year-over-year, with a record number of ordering clinicians reaching over 38,000 [22] - The company faced challenges in prenatal testing, with a decline in volume due to order management disruptions, but expects recovery in 2026 [21][22] - The mental health segment showed resilience, with GeneSight revenues impacted by UnitedHealthcare's coverage policy change but still achieving positive coverage policies across 12 payers [23] Company Strategy and Development Direction - The company is focusing on high-growth market segments and plans multiple product launches, including the expanded MyRisk panel and the AI-enhanced Prolaris test [5][10] - A significant investment of over $35 million is planned to enhance organizational efficiency and commercial capabilities, particularly in the cancer care continuum [15][60] - The company aims to strengthen its position across cancer care testing while leveraging operational strengths for sample processing and reporting [33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving high single-digit to low double-digit growth rates in 2027 and beyond, driven by new product launches and recovery in the prenatal business [39] - The company is optimistic about the potential for continued momentum in hereditary cancer testing and expects to regain share in the prenatal market [20][21] - Management emphasized the importance of execution excellence and rigorous testing before launching new products to avoid past issues [82] Other Important Information - The company plans to simplify its reporting structure to align with its refreshed strategy, focusing on cancer care continuum, prenatal health, and mental health as distinct categories [31] - The company maintains a solid balance sheet with access to $225 million in capital and intends to file a universal shelf registration [28] Q&A Session Summary Question: Confidence in long-term growth rate - Management highlighted several growth drivers for 2026, including product launches and improvements in commercial execution, expressing confidence in returning to high single-digit growth rates [38] Question: MRD launch strategy - Management indicated a selective approach for the MRD launch, focusing on user experience and operational efficiency before expanding volume [42] Question: Prenatal growth expectations - Management acknowledged a decline in prenatal volume in Q1 but expects recovery in Q2 and beyond, supported by a focused sales team and new product launches [44][76] Question: Prolaris momentum - Management noted that various initiatives, including engagement with KOLs and sales team expansion, contributed to Prolaris' growth, while also acknowledging potential favorable comparisons in Q4 [71][73]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $210 million, exceeding the high end of the pre-announced range, with a year-over-year growth of approximately 4% when excluding the impact from UnitedHealthcare's decision on GeneSight [4][24] - For the full year 2025, total revenue was $824.5 million, with over 1.5 million test reports delivered [6] - Adjusted gross margin for the fourth quarter was 70%, with adjusted EBITDA of $14.3 million and adjusted EPS of $0.04 [7][26] Business Line Data and Key Metrics Changes - Oncology revenue for the fourth quarter was $84.7 million, reflecting a 2% growth year-over-year, with MyRisk test volume growing 14% in the affected market and 11% in the unaffected market [16][18] - Prolaris revenue growth accelerated to 16% year-over-year in the fourth quarter, driven by a 12% increase in test volume [16][17] - Women's health revenue was $88.5 million, a 2% increase year-over-year, with hereditary cancer testing in the unaffected market growing by 3% and volume growth of 11% [18][19] - GeneSight generated revenues of $36.6 million with a 9% year-over-year volume growth [21] Market Data and Key Metrics Changes - The company served over 55,000 healthcare providers, with GeneSight achieving a record number of ordering clinicians exceeding 38,000 [6][21] - The prenatal testing segment experienced a decline in volume due to previous order management disruptions, but recovery is expected in 2026 [20][22] Company Strategy and Development Direction - The company is focusing on high-growth market segments and plans multiple product launches, including the expanded MyRisk panel and AI-enhanced Prolaris test [4][9] - A significant investment of over $35 million is planned to enhance organizational efficiency and commercial capabilities, particularly in cancer care [15][30] - The company aims to strengthen its position across cancer care testing while expanding its commercial capabilities and customer reach [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving high single-digit to low double-digit growth rates in 2027 and beyond, driven by new product launches and recovery in the prenatal business [39] - The company is optimistic about the ongoing demand for its products and the positive momentum in hereditary cancer testing and GeneSight volumes [23][24] Other Important Information - The company plans to simplify its reporting structure to align with its refreshed strategy, focusing on cancer care continuum, prenatal health, and mental health as distinct categories [30] - The company is preparing for the commercial launch of Precise MRD for breast cancer, with an alpha launch starting next week [12][17] Q&A Session Summary Question: Confidence in long-term growth rate - Management highlighted the drivers of growth for 2026, including product launches and improvements in commercial execution, expressing confidence in returning to high single-digit growth rates [38][39] Question: MRD launch strategy - The company plans to be selective during the alpha phase of the MRD launch, focusing on user experience and operational efficiency before scaling up [41][42] Question: Prenatal growth expectations - Management acknowledged a decline in prenatal volume in Q1 but expects recovery in Q2 and beyond, supported by a focused sales team [44][78] Question: Prolaris momentum and dynamics - Management noted that various initiatives contributed to Prolaris growth, including engagement with key opinion leaders and expansion of the sales team [72][75] Question: GeneSight ASP trends - Management indicated that the trend in average selling price (ASP) for GeneSight is expected to improve as the company engages with payers and secures positive coverage policies [88]

Financial Performance and Guidance - Preliminary Q4 2025 total revenue is expected to be between $207 million and $209 million, and full year 2025 revenue between $822 million and $824 million[51] - Total test volume growth for 2025 is approximately 1% year-over-year, with Hereditary Cancer showing 7% growth, Mental Health 6% growth, and Prenatal Health a (4)% decrease[51] - 2026 total revenue guidance is set at $860 million to $880 million, reflecting approximately 6% growth compared to the midpoint of the preliminary 2025 revenue range[53] - Adjusted gross margin for 2026 is projected to be between 68% and 69%[53] - Adjusted EBITDA for 2026 is expected to be between $37 million and $49 million, representing approximately 43% growth over the midpoint of the previous full year 2025 guidance range[53] - The company is targeting high single-digit to low double-digit percentage annual revenue growth in the long term[60] Strategic Focus and Market Expansion - The company is prioritizing the Cancer Care Continuum to drive accelerated growth and profitability[11, 60] - The company plans to leverage market-leading positions and new products to accelerate growth in markets such as Hereditary Cancer Testing (HCT), therapy selection, prostate cancer, and molecular residual disease (MRD)[13] - The total addressable market (TAM) for therapy selection, HRD (Homologous Recombination Deficiency) & CGP (Comprehensive Genomic Profiling) is estimated at $8 billion, with an estimated annual market growth of 14-17%[13] - The MRD market has a TAM of $21 billion with an estimated annual market growth of 15-20%[13] - The company is expanding its testing menu to serve more of the Cancer Care Continuum, including hereditary cancer screening, diagnosis & therapy selection, and molecular residual disease monitoring[15, 16]

Myriad Genetics FY Conference Summary Company Overview - **Company**: Myriad Genetics (NasdaqGS:MYGN) - **Date of Conference**: December 02, 2025 Key Industry Insights - **Hereditary Cancer Market**: The unaffected population represents a $5 billion market opportunity, with significant growth potential as it remains less than a third penetrated [2][21] - **Mental Health Market**: Myriad Genetics is a market leader in mental health testing, with plans to maintain growth despite challenges from competitors [16][19] Core Company Strategies - **Focus on Cancer Care**: The updated strategy emphasizes a concentrated effort on the cancer care continuum, while managing growth in prenatal and mental health segments [3][8] - **Product Development**: Introduction of new products such as FirstGene and Early Access for prenatal screening, and an updated MyRisk product with 63 genes [7][10] - **Execution Excellence**: Acknowledgment of the need for improved execution in product development and market launch processes [3][4] Financial Performance - **Growth Metrics**: Mid-single-digit growth observed in GeneSight tests, with a return to growth in hereditary cancer testing after previous challenges [6][21] - **Revenue Projections**: GeneSight expected to generate over $150 million in revenue, with potential for mid-single to low double-digit growth rates [16][17] Competitive Landscape - **Market Positioning**: Myriad Genetics aims to differentiate itself from competitors like Natera and BillionToOne by leveraging its comprehensive product offerings and customer support [8][9] - **Guideline Engagement**: Active collaboration with Key Opinion Leaders (KOLs) to clarify NCCN guidelines and enhance the adoption of Myriad's Prolaris test for prostate cancer [12][13] Product Pipeline and R&D Focus - **MRD Testing**: Introduction of the Precise MRD assay, expected to launch in the first half of 2026, with a focus on low-shedding cancers [25][26] - **Partnerships**: Collaborations with Pathomic to accelerate R&D and market entry for new tests [29][33] - **Clinical Studies**: Over 20 studies in MRD across various cancer indications, with results expected to enhance clinical utility and guideline positioning [28][30] Challenges and Opportunities - **Reimbursement Issues**: Navigating reimbursement challenges, particularly with UnitedHealth's policy, while expanding payer coverage [16][20] - **Market Activation**: Efforts to activate the unaffected hereditary cancer market through improved workflows and sales strategies [22][23] Conclusion - Myriad Genetics is strategically positioning itself for growth in the hereditary cancer and mental health markets, with a strong focus on execution excellence and product innovation. The company is optimistic about its future prospects, particularly with the anticipated launch of new products and ongoing collaborations.

Financial Data and Key Metrics Changes - The company reported revenue of $213 million for Q2 2025, representing a 5% year-over-year increase, excluding the impact of UnitedHealthcare's decision on GeneSight and the divested European ENDOPREDICT business [7][34] - Adjusted gross margins improved to 71.5%, an increase of 140 basis points compared to the previous year [12][38] - Adjusted EBITDA for the quarter was $14.5 million, reflecting a 24% growth year-over-year [12][45] Business Line Data and Key Metrics Changes - Hereditary cancer revenue grew by 5% for the quarter, with a 10% volume growth in the oncology channel [23] - GeneSight volume increased by 5% year-over-year, recovering from low single digits [10][31] - Prenatal products, PREQUEL and FORESIGHT, saw a 7% decline in volume year-over-year due to challenges with an order management system, which has since been resolved [11][29] Market Data and Key Metrics Changes - The oncology market showed strong growth, with hereditary cancer testing volume increasing by 14% year-over-year [9][25] - The prenatal health market is expected to grow at or above market rates, driven by new product launches and expanded payer coverage [19][30] - Mental health testing through GeneSight generated revenues of $38 million, with a 5% volume growth year-over-year [31] Company Strategy and Development Direction - The company is focusing on the cancer care continuum (CCC) as a strategic priority to drive accelerated growth and profitability [14][15] - Three strategic pillars include enhancing hereditary cancer testing, growing prenatal and mental health revenues, and maintaining financial discipline [18][20] - The company plans to increase investments in R&D and enhance commercial capabilities to support the CCC strategy [17][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's potential and the progress made in addressing previous challenges [6][8] - The company raised its guidance for 2025 based on positive Q2 results and ongoing improvements in execution [13][45] - Management emphasized the importance of strategic partnerships and operational excellence to drive future growth [17][22] Other Important Information - The company secured a $200 million term loan from OrbiMed, providing liquidity and flexibility for growth initiatives [13][43] - A significant non-cash impairment charge of $317 million was recognized due to a decline in market capitalization, but this does not reflect a change in business outlook [39][40] Q&A Session Summary Question: Request for more specific KPIs related to the strategic review - Management acknowledged the need for more quantifiable KPIs and plans to share these in the upcoming months [52][56] Question: Clarification on portfolio divestitures - Management indicated satisfaction with the current portfolio and stated that periodic reviews will be conducted to assess strategic alignment [53][56] Question: Impact of UnitedHealthcare's coverage on GeneSight - Management confirmed ongoing discussions with UnitedHealthcare and plans to submit new clinical data for review in the fall [60][64] Question: Clarification on the timing of the MRD test launch - Management confirmed an early access launch for the MRD test in the first half of 2026, with ongoing clinical studies [66][68] Question: Guidance for the back half of the year - Management indicated that the guidance raise is based on improved execution and recovery from previous challenges, particularly in hereditary cancer testing [88][90]

Core Viewpoint - Myriad Genetics, Inc. is focusing on expanding its companion diagnostics and oncology business while facing challenges from the end of UnitedHealthcare's GeneSight coverage and macroeconomic pressures [1][8]. Company Performance - Myriad Genetics' shares have decreased by 79% over the past year, contrasting with a 12.6% decline in the industry and a 9.2% gain in the S&P 500 [2]. - The company has a market capitalization of $463.7 million and an earnings yield of 0.2%, outperforming the industry's -29.4% yield [2]. - Myriad Genetics has consistently surpassed earnings estimates over the last four quarters, achieving an average surprise of 210% [2]. Growth Opportunities - There is significant potential in oncology testing, particularly through partnerships and new offerings such as the integrated program with Gabbi and the addition of AI technology from PATHOMIQ [3][4]. - Myriad Genetics has seen an 11% year-over-year growth in MyRisk testing volume and plans to launch new products like the Prequel and Precise MRD tests [5]. - The women's health segment, especially MyRisk cancer screening, targets approximately 50 million women in the U.S. who meet hereditary cancer testing guidelines, with prenatal testing revenues increasing by 11% year over year [6]. Strategic Initiatives - The company is investing in electronic medical records (EMR) solutions to enhance customer and patient experiences, which is expected to drive future volume growth [9]. - Myriad Genetics has been granted two new patents for its MRD test, building on previous patents, and plans to launch the Precise MRD test in the first half of 2026 [4]. Financial Health - As of the first quarter of 2025, Myriad Genetics had cash and cash equivalents of $92 million and no short-term debt, indicating strong solvency [10]. Challenges - The end of UnitedHealthcare's coverage for the GeneSight test has resulted in a 20% year-over-year revenue decline for this product [12]. - The company faces macroeconomic pressures, including rising labor costs and tariffs, which could impact profitability [11].

Financial Performance - Q1 2025 - Total revenue decreased by 3% year-over-year (YOY) [6, 24], but increased by 5% YOY excluding specific factors like UNH GeneSight impact, EndoPredict divestiture, and a one-time retroactive coverage benefit from Q1 2024 [6] - Adjusted Gross Margin increased by 50 basis points YOY [24], reaching 69% in Q1 2025 [24, 40] - Adjusted Operating Expenses increased by 1% YOY [7, 24], with $140.6 million in Q1 2025 compared to $139.1 million in Q1 2024 [42] - Adjusted EPS was $(0.03) in Q1 2025, compared to $(0.01) in Q1 2024 [24, 45] - Adjusted EBITDA was $(0.1) million in Q1 2025, a decrease from $4 million in Q1 2024 [29, 47] - Adjusted free cash flow was $(18.7) million in Q1 2025, compared to $(17.9) million in Q1 2024 [30, 49] Segment Performance - Q1 2025 - Hereditary Cancer testing (HCT) revenue decreased by 2% YOY [11, 12], while HCT affected population revenue and volume grew by 0% and 5% YOY, respectively [12] - MyRisk with RiskScore testing revenue and volume in the affected population grew by 4% and 11% YOY, respectively [12, 15] - Prenatal revenue increased by 11% YOY [10], driven by Foresight and Prequel (+10% volume growth) [6, 18] - GeneSight testing revenue decreased by 20% YOY [12], while testing volume grew by 2% YOY [12] Updated 2025 Financial Guidance - Total revenue guidance lowered to a range of $807 million - $823 million [32], a $35 million reduction at the midpoint [7] - Adjusted operating expenses guidance moderated to a range of $555 million - $565 million [32], a $25 million reduction at the midpoint [7] - Adjusted EPS guidance midpoint is at breakeven, ranging from $(0.02) to $0.02 [7, 32]